Skip to content
OpenCapital
Get started

Zoetis ZTS Vaccines — Revenue

Other product segments

Horses
$5.8B+13.9%
Dogs and Cats
$1.35B+11.6%
Parasiticides
$586M+2.4%
Cattle
$399M-0.5%
Dermatology
$349M-7.9%
Anti-infectives
$241M+1.3%
Pain and sedation
$203M-1.9%
Other pharmaceutical
$158M0.0%
Swine
$128M-7.9%
Animal health diagnostics
$117M+12.5%
Poultry
$117M-7.9%
Other Non Pharmaceuticals
$66M-7.0%
Fish
$65M+4.8%
Contract manufacturing & human health
$23M-23.3%
Sheep and other
$17M+6.3%

Similar metrics at other companies

Phibro Animal Health logo
PAHCVaccines — Revenue
$38.63M+15.7%
Phibro Animal Health logo
PAHCAnimal Health — Revenue
$291.23M+12.7%
Novavax logo
NVAXProduct sales — Total Revenue
$42.2M-93.2%
Novavax logo
NVAXSupply sales — Total Revenue
$32.64M+139%
Cencora logo
CORAnimal Health — Revenue
$1.44B+5.3%
Elanco Animal Health Inc. logo
ELANFarm Animal: — Revenue
$642M+17.6%

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$31.9B-54.6%
Enterprise value$39.95B-47.2%
P/E12.1×-15.1×
P/S3.4×-4.1×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's vaccines — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's vaccines — revenue?
Zoetis (ZTS) reported vaccines — revenue of $519M in Q1 2026.
How has Zoetis's vaccines — revenue changed year-over-year?
Zoetis's vaccines — revenue increased by 18.2% year-over-year, from $439M to $519M.
What is the long-term trend for Zoetis's vaccines — revenue?
Over 4 years (2021 to 2025), Zoetis's vaccines — revenue has grown at a 3.9% compound annual growth rate (CAGR), from $1.67B to $1.95B.
What does vaccines — revenue mean?
This metric represents the total net sales generated from the sale of biological preparations designed to provide immunity against infectious diseases in animals. It encompasses revenue from both companion and livestock vaccine portfolios, reflecting the company's ability to capture market share in the animal health preventative care space. This revenue stream is a critical indicator of the firm's competitive positioning in the global animal health market.